The global obesity drug market is undergoing a structural shift as the U.S. Food and Drug Administration cracks down on mass marketing of compounded medications using the same active ingredients as Wegovy. Experts say the FDA's action signals the industry has moved from a seller's market into full-scale competition. With Novo Nordisk, the market leader behind Wegovy, publicly acknowledging potential earnings slowdown, analysts say the obesity drug market is becoming a red ocean.
According to Reuters and other outlets on the 8th, FDA Commissioner Martin Makary issued a statement on the 7th (local time) announcing strong enforcement against promotion and sales of unapproved compounded drugs as if they were equivalent to or generic versions of approved medications. Makary specifically cited the widespread use of glucagon-like peptide-1 (GLP-1) active ingredients in unapproved compounded drugs and their large-scale online marketing as problematic. "If these violations are not properly corrected, we will pursue additional legal actions including seizure and injunctions," he warned.
Immediately following the FDA statement, telehealth company Hims & Hers discontinued its compounded semaglutide pills, which it had promoted as using the same active ingredient as Wegovy. Hims had announced on the 5th it would sell a compounded version of Wegovy pills at $49 per month (approximately 70,000 won)—one-third the price of Wegovy—drawing significant attention. Share prices of major pharmaceutical companies selling obesity treatments, including Novo Nordisk and Eli Lilly, subsequently plunged.
Experts forecast that U.S. health authorities will tighten regulations on compounded drugs following this incident. Compounded drugs are medications prepared by adjusting dosages of existing pharmaceutical ingredients and can be released without FDA approval or clinical trials. Due to potential safety concerns, the Federal Food, Drug, and Cosmetic Act permits compounded drugs only in special circumstances, such as drug shortages or patient allergies to commercial medications.
The FDA's action is seen as aligned with recent changes in the obesity drug supply environment. The improved supply conditions for semaglutide (brand names Wegovy and Ozempic) and tirzepatide (Mounjaro and Zepbound) injectable products are believed to have influenced the FDA's decision.
Novo Nordisk's recent downward revision of its earnings outlook is interpreted in the same context. On the 3rd (local time), Novo Nordisk announced that 2026 sales and operating profit are expected to decline 5-13% year-over-year on a constant currency basis. The company faces inevitable price cuts as obesity drug development competition intensifies and the U.S. government pressures pharmaceutical prices downward. Following the earnings announcement, Novo Nordisk shares plunged more than 14% in a single day on the New York Stock Exchange. Industry observers interpreted this not as weakening competitiveness of a specific product, but as a signal that the obesity drug market has entered a phase of price competition and alternative technology proliferation. What was once viewed as a monopolistic growth industry is rapidly transitioning to a structure where profitability faces pressure amid development competition and diversification of drug formulations.
However, the direct impact of the FDA action on the Korean pharmaceutical industry is expected to be limited. Korean pharmaceutical companies are developing obesity treatments based on the premise that the semaglutide substance patent remains valid in Korea until June 2028. Nevertheless, as patents begin expiring sequentially this year in countries including China and Brazil, analysts point out that intensifying global price competition could affect Korean development strategies in the medium to long term.
The outlook on Korean obesity drug development conditions is also expected to become more cautious. Even if Korean companies succeed in developing generics, optimism about profitability is difficult when even Novo Nordisk has lowered its earnings forecast under pricing pressure. Among Korean pharmaceutical companies, Hanmi Pharmaceutical, Chong Kun Dang, LG Chem, Dong-A ST, HK inno.N, and others are currently developing obesity treatments including GLP-1-based drugs.
Experts point out that as global obesity drug market competition rapidly intensifies, Korean pharmaceutical companies now face an environment where they must secure price competitiveness alongside technological capability. The intensifying competition in the obesity drug market is expected to signal to the global pharmaceutical industry that obesity treatments are no longer a "golden goose industry." An industry official said, "As global big pharma companies including Novo Nordisk strengthen their defensive strategies, Korean obesity drug developers must also engage in a survival competition emphasizing technological capability and differentiation in a market environment that has become a red ocean."